Lakewood-Amedex reports positive preclinical results for Bisphosphocin infection treatments
- Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) reported positive preclinical findings for its Bisphosphocin compounds in urinary tract and pulmonary infection models.
- Bladder-administered Nu-8 inhibited E. coli growth by up to 97% in infected rodents.
- The company plans additional development work to select a candidate for early clinical testing.
Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) announced positive preclinical results for its Bisphosphocin compounds in animal models of urinary tract and pulmonary infections.
In urinary tract infection studies, Nu-8 was administered directly into the bladder as a 10% solution.
The treatment inhibited E. coli growth by as much as 97% in infected rodents, while the vehicle control showed no comparable effect.
The company also reported activity from aerosol formulations in animal models of pulmonary infections caused by Acinetobacter species, Pseudomonas aeruginosa and Aspergillus fumigatus.
Laboratory testing further showed that the Bisphosphocin compounds were active against resistant bacteria associated with urinary tract and pulmonary infections, as well as organisms capable of forming biofilms.
Lakewood-Amedex said it plans to conduct additional development work to identify a lead candidate suitable for early clinical development.
The findings expand the potential application of the company’s Bisphosphocin platform beyond its existing development programs and could support further investigation of localized antimicrobial treatments for difficult-to-treat infections.
Separately, Lakewood-Amedex is evaluating Nu-3 topical gel in an ongoing Phase 2a clinical trial for mildly infected diabetic foot ulcers.
The company expects to report topline results from the Nu-3 study in the first quarter of 2027.
The preclinical findings remain early-stage results, and additional studies will be required to establish whether the compounds can demonstrate safety and efficacy in humans.
